Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...
Routines to create rounded corners, with either circular rounding, or continuous curvature rounding with no sudden curvature transitions. Provides rounding of corners or rounding that preserves corner ...
1. Current NAV: The Current Net Asset Value of the Axis Bluechip Fund as of Apr 01, 2025 is Rs 56.39 for Growth option of its Regular plan. 2. Returns: Its trailing returns over different time periods ...
1 Department of Pharmaceutical Sciences, Artificial Intelligence and Drug Discovery Core Laboratory for District of Columbia Center for AIDS Research (DC CFAR), College of Pharmacy, Howard University, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results